SEARCH

SEARCH BY CITATION

References

  • 1
    Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012; 8: 348357.
  • 2
    Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520331.
  • 3
    Sellares J, De Freitas D, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and non-adherence. Am J Transplant 2012; 12: 388399.
  • 4
    Gorer PA. The detection of antigenic differences in mouse erythrocytes by the employment of immune sera. Br J Exp Pathol 1936; 17: 4250.
  • 5
    Gorer PA. The role of antibodies in immunity to transplanted leukemia in mice. J Pathol Bacteriol 1942; 54: 5165.
  • 6
    Gorer PA, O'Gorman P. The cytotoxic activity of isoantibodies in mice. Transplant Bull 1956; 3: 142143.
  • 7
    Kissmeyer-Nielsen F, Olsen S, Peterson VP, Fjeldborg O. Hyperacute rejection of kidney allografts associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2: 662665.
  • 8
    Starzl TE, Lerner RA, Dixon FJ, Groth CG, Brettschneider L, Terasaki PI. Shwartzman reaction after human renal homotransplantation. N Engl J Med 1968; 278: 642647.
  • 9
    Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735780.
  • 10
    Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665673.
  • 11
    Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I antibody response. I: Clinical and pathologic features of anti-class I-mediated rejection. Transplant 1990; 49: 8591.
  • 12
    Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplant 1992; 53: 550555.
  • 13
    Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Transplant 1996; 61: 15861592.
  • 14
    Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464470.
  • 15
    Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 13331338.
  • 16
    Feucht HE. Complement C4d in graft capillaries—the missing link in the recognition of humoral alloreactivity. Am J Transplant 2003; 3: 646652.
  • 17
    Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 22082214.
  • 18
    Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 25612570.
  • 19
    Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplant 2008; 8: 492496.
  • 20
    Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 5665.
  • 21
    Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574582.
  • 22
    Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 23712380.
  • 23
    Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 11681179.
  • 24
    Furness PN, Taub N. International variation in the interpretation of renal transplant biopsies: Report of the CERTPAP Project. Kidney Int 2001; 60: 19982012.
  • 25
    Furness PN, Taub N, Assmann KJ, et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol 2003; 27: 805810.
  • 26
    Gibson IW, Gwinner W, Brocker V, et al. Peritubular capillaritis in renal allografts: Prevalence, scoring system, reproducibility and clinicopathological correlates. Am J Transplant 2008; 8: 819825.
  • 27
    Bray RA, Gebel HM. Strategies for human leukocyte antigen antibody detection. Curr Opin Organ Transplant 2009; 14: 392397.
  • 28
    Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11: 896906.
  • 29
    Seemayer CA, Gaspert A, Nickeleit V, Mihatsch MJ. C4d staining of renal allograft biopsies: A comparative analysis of different staining techniques. Nephrol Dial Transplant 2007; 22: 568576.
  • 30
    Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure 1. Transplant 2010; 90: 6874.
  • 31
    Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting Report: New concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563570.
  • 32
    Cardoso F, Van't VL, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 2008; 26: 729735.
  • 33
    Yang M, Rajan S, Issa AM. Cost effectiveness of gene expression profiling for early stage breast cancer: A decision-analytic model. Cancer 2012; 118: 62986299.
  • 34
    Prat A, Parker JS, Fan C, et al. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 2012; 23: 28662867.
  • 35
    Hartmann S, Gerber B, Elling D, Heintze K, Reimer T. The 70-gene signature as prognostic factor for elderly women with hormone receptor-positive, HER2-negative breast cancer. Breast Care 2012; 7: 1924.
  • 36
    Limmathurotsakul D, Turner EL, Wuthiekanun V, et al. Fool's gold: Why imperfect reference tests are undermining the evaluation of novel diagnostics: A reevaluation of 5 diagnostic tests for leptospirosis. Clin Infect Dis 2012; 55: 322331.
  • 37
    Reitsma JB, Rutjes AW, Khan KS, Coomarasamy A, Bossuyt PM. A review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard. J Clin Epidemiol 2009; 62: 797806.
  • 38
    McAdam AJ. Discrepant analysis: How can we test a test?. J Clin Microbiol 2000; 38: 20272029.
  • 39
    Reeve J, Einecke G, Mengel M, et al. Diagnosing rejection in renal transplants: A comparison of molecular- and histopathology-based approaches. Am J Transplant 2009; 9: 18021810.
  • 40
    Sis B, Jhangri G, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 23122323.
  • 41
    Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10: 18121822.
  • 42
    Halloran PF, de Freitas DG, Einecke G, et al. The molecular phenotype of kidney transplants. Am J Transplant 2010; 10: 22152222.
  • 43
    Hidalgo LG, Sellares J, Sis B, Mengel M, Chang J, Halloran PF. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant 2012;12: 11801191.
  • 44
    Reeve J, Sellares J, Mengel M, et al. Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant In press 2012.
  • 45
    Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007; 7: 27122722.
  • 46
    Sis B, Mengel M, Haas M, et al. Banff “09 Meeting Report: Antibody mediated graft deterioration and implementation of Banff Working Groups. Am J Transplant 2010; 10: 464471.
  • 47
    de Freitas DG, Sellares J, Mengel M, et al. The nature of biopsies with “Borderline Rejection” and prospects for eliminating this category. Am J Transplant 2012; 12: 191201.
  • 48
    Famulski KS, de Freitas DG, Kreepala et al. Molecular phenotypes of acute kidney injury in human kidney transplants. JASN 2012; 23: 948958.
  • 49
    Mengel M, Reeve J, Bunnag S, et al. Molecular correlates of scarring in kidney transplants: The emergence of mast cell transcripts. Am J Transplant 2009; 9: 169178.
  • 50
    Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. 1st ed. New York: Springer Science+Business Media; 2009.
  • 51
    Torgo L. Data Mining with R: Learning with Case Studies. 1st Ed. Voca Raton, FL: CRC Press, 2010.
  • 52
    Shi L, Campbell G, Jones WD, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010; 28: 827838.
  • 53
    Kim JH. Estimating classification error rate: Repeated cross-validation, repeated hold-out and bootstrap. Comput Stat Data Anal 2009; 53: 37353745.
  • 54
    Kashiwazaki M, Tanaka T, Kanda H, et al. A high endothelial venule-expressing promiscuous chemokine receptor DARC can bind inflammatory, but not lymphoid, chemokines and is dispensable for lymphocyte homing under physiological conditions. Int Immunol 2003; 15: 12191227.
  • 55
    Fang Y, Davies PF. Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol 2012; 32: 979987.
  • 56
    Agresti A. Categorical Data Analysis. 2nd Ed. New York: John Wiley & Sons; 2002.
  • 57
    Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753760.
  • 58
    Loupy A, Sellares J, Hidalgo L, Legendre C, Halloran PF. Determinants of progression to transplant glomerulopathy in ABMR: A combined clinical-molecular approach. Am J Transplant 2012; 12: 44. Ref Type: Abstract.
  • 59
    Radaev S, Sun P. Recognition of immunoglobulins by Fcgamma receptors. Mol Immunol 2002; 38: 10731083.
  • 60
    Ogawa K, Tanaka K, Ishii A, et al. A novel serum protein that is selectively produced by cytotoxic lymphocytes. J Immunol 2001; 166: 64046412.
  • 61
    Park WD, Grande JP, Ninova D, et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003; 3: 952960.
  • 62
    Bach FH, Ferran C, Hechenleitner P, et al. Accommodation of vascularized xenografts: Expression of “protective genes” by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997; 3: 196204.
  • 63
    Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med 2012; 366: 489491.